Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evusheld and Regkirona for COVID-19 Omicron Strain
NCT05982704Phase 4Unknown
- Sponsor
- State Budgetary Healthcare Institution "City Clinical Hospital No. 52 of the Moscow Healthcare Department"
- Start
- Aug 2022
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tixagevimab + cilgavimab in coronavirus disease 2019 (COVID-19), sponsored by State Budgetary Healthcare Institution "City Clinical Hospital No. 52 of the Moscow Healthcare Department". Status: unknown.
02
Drugs
tixagevimab + cilgavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05982704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05982704.